Immunovive utilizes the BinderGen platform to rapidly generate diverse, target-specific monoclonal antibodies in vivo. This proprietary platform delivers affinity-ranked VH/VL sequences in six weeks, significantly accelerating biotherapeutics discovery timelines. The resulting high-quality binders support downstream preclinical development, lead optimization, and multimodality engineering for immunotherapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody discovery methods can be slow, expensive, and encumbered by intellectual property restrictions, hindering rapid development of novel biotherapeutics. Many researchers face challenges in accessing diverse antibody candidates quickly and retaining full rights for downstream drug development.
Solution
Immunovive offers a fee-for-service antibody discovery platform, BinderGen™, that delivers high-affinity monoclonal hybridomas derived from in vivo sources within six weeks. The platform employs robust immunization protocols and efficient recovery of rare binders, optimized for hit retention and native VH-VL pairing. Clients retain 100% ownership of the resulting antibodies, facilitating downstream applications such as target validation, proof-of-concept studies, lead optimization, and multimodality engineering. The service provides drug-like protein deliverables, accelerating biotherapeutics discovery by eliminating access barriers and IP encumbrances.
Target Audience
The primary customers are biotherapeutic investigators and researchers in the life science industry seeking rapid access to diverse, high-affinity antibodies for drug development applications.
Features
- Rapid in vivo antibody discovery platform delivering monoclonal hybridomas in 6 weeks
- Robust immunization protocols for diverse antibody generation
- Efficient recovery of rare binders with optimized hit retention
- Native VH-VL pairing to maintain antibody integrity
- Drug-like protein deliverables suitable for therapeutic development
- Fee-for-service model with no intellectual property restrictions